Compare First Solar, Inc. (FSLR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? First Solar, Inc. trades at $227.3 (market cap $25.89B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: First Solar, Inc. is far larger — about 14.3× Recursion Pharmaceuticals Inc's market cap, and First Solar, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FSLR | RXRX | |
|---|---|---|
Market Cap | $25.89B | $1.81B |
Sector | Technology | Health |
52-Week High | $318.30 | $6.79 |
52-Week Low | $180.05 | $2.84 |
Enterprise Value | $24.36B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $239.33, down 4.29% today, with a bullish technical signal from moving averages and a consensus analyst price target of $282.07. The company reported strong revenue growth to $5.22B in 2025, with a net income margin of 32.47%, though it missed Q4 2025 EPS estimates. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty alongside positive analyst upgrades.
The outlook remains positive due to robust profitability and upward earnings revisions, but risks include legal challenges and potential volatility from overbought technical conditions. Investors should weigh solid fundamentals against near-term sentiment pressures.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
